Jessica M. Fogel

PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial

Connie Celum, Sybil Hosek, Mandisa Tsholwana et al. · PLoS Medicine · 2021 · 172 citations · Full text

Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083

Mark A. Marzinke, Beatriz Grinsztejn, Jessica M. Fogel et al. · The Journal of Infectious Diseases · 2021 · 120 citations · Full text

Undisclosed Antiretroviral Drug Use in a Multinational Clinical Trial (HIV Prevention Trials Network 052)

Jessica M. Fogel, Lei Wang, Teresa L. Parsons et al. · The Journal of Infectious Diseases · 2013 · 79 citations · Full text

Pharmacotherapy, Human Immunodeficiency Virus, Preventive Medicine +16

Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial

Susan H. Eshleman, Sarah E. Hudelson, Andrew D. Redd et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2016 · 75 citations · Full text

Sexual Health, Antiretroviral Therapy, Preventive Medicine +14

Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084

Susan H. Eshleman, Jessica M. Fogel, Estelle Piwowar‐Manning et al. · The Journal of Infectious Diseases · 2021 · 67 citations · Full text